ESR1 and breast carcinoma: The high expression of SLC7A5 promotes the proliferation of ER+ breast cancer cells, leucine absorption, and the induction of tamoxifen resistance, making SLC7A5 a necessary and sufficient condition for developing resistance to tamoxifen therapy.